Background: Chest pain is one of the most common complaints among patients presenting to the emergency department (ED). Causes of chest pain can be benign or life threatening, making accurate risk stratification a critical issue in the ED. In addition to the use of established clinical scores, prior studies have attempted to create predictive models with heart rate variability (HRV). In this study, we proposed heart rate n-variability (HRnV), an alternative representation of beat-to-beat variation in electrocardiogram (ECG) and investigated its association with major adverse cardiac events (MACE) for ED patients with chest pain.
Background
Chest pain is one of the most common presenting complaints in the emergency department (ED) [1, 2] , which may be due to life-threatening myocardial infarction (MI) or benign musculoskeletal pain [3] . Majority of chest pain patients are subjected to extensive diagnostic tests to rule out acute coronary syndrome (ACS), resulting in oftentimes, unnecessary prolonged and costly ED admission, since only a small proportion of these patients will eventually receive a diagnosis of ACS [3] . Hence, early identification of chest pain patients at high-risk of developing adverse cardiac events has been a pressing issue to contend with in the ED. Several established clinical scores have been used for risk stratifying chest pain patients in the ED [4, 5] , including the History, ECG, Age, Risk factors and Troponin (HEART) [6] , the Thrombolysis in Myocardial Infarction (TIMI) [7] , and the Global Registry of Acute Coronary Events (GRACE) [8] scores. Of the available clinical scores, the HEART score is the most accurate and widely used [5, [9] [10] [11] [12] . Further research has focused on developing risk score-based clinical pathways for safe discharge of low-risk patients [1, 3, 13, 14] .
In a recent review of clinical scores for ED patients with chest pain [5] , heart rate variability (HRV) provided an alternative approach to build predictive models for accurate risk stratification [15] [16] [17] . HRV is a widely adopted tool for evaluating changes in cardiac autonomic regulation, and has been shown to be strongly associated with the autonomic nervous system (ANS) [18] [19] [20] . HRV analysis characterizes the beat-to-beat variation in an electrocardiogram (ECG) by utilizing time domain, frequency domain, and nonlinear analyses [19] . Reduced HRV has been found to be a significant predictor of adverse cardiac outcomes [21] . Given the complexity of quantifying HRV representation, several tools such as the PhysioNet Cardiovascular Signal Toolbox [22] and Kubios HRV [23] have been developed to standardize HRV analyses.
Based on the principle of parameter calculation on normal R-R intervals (RRIs; in this paper, RRIs are equivalent to normal-to-normal [NN] intervals, in which abnormal beats have been 4 removed), HRV analysis generates only one set of parameters from a fixed length of ECG record. This limits the amount of information that can be extracted from raw ECG signals. In this paper, we proposed a novel representation of beat-to-beat variation, named as heart rate n-variability (HRnV) [24] to characterize RRIs from a different perspective. With the use of HRnV measures, multiple sets of parameters are calculated from the same ECG record, which significantly increases the amount of extracted information. Our study is the first clinical application of the HRnV representation, in which the value of this novel measure is evaluated in risk stratification of chest pain patients in the ED. We hypothesize that HRnV is closely related to conventional HRV while providing supplementary information that is associated with adverse cardiac events. Further, we will investigate the potential use of HRnV parameters to develop risk prediction tools.
Methods

Study Design and Setting
We conducted a retrospective analysis of data collected in our previous study on risk stratification of chest pain patients in the ED [9] . A convenience sample of patients was recruited at the ED of Singapore General Hospital between September 2010 and July 2015. This is a tertiary hospital with around-the-clock primary percutaneous coronary intervention capabilities and a median door-to-balloon time of 101 minutes [25] . At ED triage, patients are assigned a Patient Acuity Category Scale (PACS) score ranging from 1 to 4 to indicate the urgency for consultation; smaller number means higher acuity. In this study, patients >20 years old who presented to the ED with chief complaint of chest pain and were triaged to PACS 1 or 2 were included. Patients were excluded if they had ST-elevation myocardial infarction (STEMI) or an obvious non-cardiac etiology of chest pain diagnosed by the primary emergency physician. Patients were also excluded if their ECGs had high percentage of noise or they were in non-sinus rhythm; these criteria were applied to ensure the quality of HRV and HRnV analyses. The ethical approval was obtained from the Centralized Institutional Review Board (CIRB, Ref: 2014/584/C) of SingHealth, the largest public healthcare system in Singapore that includes the Singapore General Hospital as a key partner.
In the ethical approval, patient consent was waived.
Data Collection
5
During the data collection period, five to six-minute single-lead (lead II) ECG tracings were retrieved from the X-Series Monitor (ZOLL Medical Corporation, Chelmsford, MA). The first set of vital signs and troponin values from the recruited patients were extracted from the hospital's electronic health records (EHR). In this study, high-sensitivity troponin-T was used, and an abnormal value was defined as >0.03 ng/mL [26] ; it was further stratified into three groups and coded as 0 if the value was ≤0.03 ng/mL, 1 if the value was between 1 and 3 times the normal limit, and 2 if the value was >3 times the normal limit. Additionally, the patients' first 12-lead ECGs were interpreted by two independent clinical reviewers.
Pathologic ST-elevation, ST-depression, T-wave inversions, and Q-waves were recorded.
Patient demographics, medical history, and information required for computing the HEART, TIMI, and GRACE scores were retrospectively reviewed and obtained from EHR.
Proposed HRnV Representation of Beat-to-Beat Variation in ECG
HRnV: A Novel Measure with Non-Overlapped RRIs Prior to introducing the new HRnV measure, we define a new type of RRI called RRnI, where 1 ≤ ≤ , and ≪̂. ̂ is the total number of RRIs. The definition of RRnI is illustrated in Figure 1a . When = 1, RRnI becomes conventional RRI, that is, RR1I is equal to RRI.
When > 1, every adjacent RRI is connected to form a new sequence of RRnIs. By using this strategy, we can create a maximum number of ( − 1) new RRnI sequences from conventional single RRI sequence. With these newly generated RRnI sequences, the calculation of HRnV parameters is straightforward and can be accomplished by applying established quantitative methods including time domain analysis, frequency domain analysis, and nonlinear analysis [18, 19] . In describing this new measure, we use the term "HRnV" prior to parameter names to indicate that these parameters are calculated from RRnI sequences. As noted in the above, HRnV is a novel measure based on newly generated, nonoverlapped RRnIs. The computed HRnV parameters include but are not limited to the following: the average of RRnIs (HRnV mean NN), standard deviation of RRnIs (HRnV SDNN), square root of the mean squared differences between RRnIs (HRnV RMSSD), the number of times that the absolute difference between two successive RRnIs exceeds 50 ms (HRnV NN50), HRnV NN50 divided by the total number of RRnIs (HRnV pNN50), the integral of the RRnI histogram divided by the height of the histogram (HRnV triangular index), low frequency power (HRnV LF power), high frequency power (HRnV HF power), 6 approximate entropy (HRnV ApEn), sample entropy (HRnV SampEn), and detrended fluctuation analysis (HRnV DFA), among others. Notably, two new parameters NN50n and pNN50n are created, where 50×n ms is set as the threshold to assess the difference between pairs of consecutive RRnIs.
HRnVm: A Novel Measure with Overlapped RRIs
Like RRnI that is used in HRnV, to define the HRnVm measure we introduce another type of RRI called RRnIm, where 1 ≤ ≤ , 1 ≤ ≤ − 1, and ≪̂. In the RRnIm sequence, is used to indicate the level of overlap between consecutive RRnIm sequences. As illustrated in Figure 1b , ( − ) RRIs form the overlapped portions. When = , RRnIm becomes RRnI; therefore, the upper limit of is − 1. By controlling the overlap among these newly generated RRnIm sequences, we can create a maximum number of ( × ( − 1)/2) RRnIm sequences (excluding the RRnI sequence) from conventional single RRI sequence. For each of the newly created RRnIm sequences, we apply time domain analysis, frequency domain analysis, and nonlinear analysis to calculate HRnVm parameters. We add the term "HRnVm" prior to the parameters to denote that they are computed from RRnIm sequences. For example, the average RRnIm intervals and the sample entropy are written as HRnVm mean NN and HRnVm SampEn, respectively. The HRnVm measure extracts additional information than HRnV does, by adopting a strategy of controlling sequence overlap.
HRnV Analysis and Parameter Calculation
We developed the HRnV-Calc software suite (https://github.com/HRnV) to calculate HRnV parameters. The HRnV-Calc software integrates functions from the PhysioNet Cardiovascular Signal Toolbox [22] to perform standardized ECG signal processing and QRS complex detection. Given the short ECG records in this study, the upper limit of was set as three; thus, six sets of parameters were calculated, namely HRV, HR2V, HR2V1, HR3V, HR3V1, and HR3V2.
Clinical Outcomes
The primary endpoint in this study was a composite outcome of major adverse cardiac events (MACE) [27] , including all-cause death, acute myocardial infarction (AMI), and revascularization (coronary artery bypass graft [CABG] or percutaneous coronary intervention [PCI]) within 30 days of ED presentation. 7
Statistical Analysis
Continuous variables were presented in terms of mean and standard deviation and compared between the two categories of the primary outcome (MACE) using two-sample t-test.
Categorical variables were presented in terms of frequency and percentage and compared between the two categories of the primary outcome (MACE) using chi-square test. A statistically significant difference was defined as p<0.05. To evaluate the HRnV parameters and other risk factors, we conducted univariable and multivariable analyses and subsequently developed simple prediction models using traditional logistic regression. In building the HRnV prediction model, we selected candidate variables with p<0.2 in the univariable analysis and fed them into multivariable stepwise logistic regression. To evaluate the predictive performance, we used leave-one-out cross-validation (LOOCV) to conduct the analysis. 
Results
A total of 795 patients were selected from the originally recruited 922 patients [9] . 28 were excluded for ECG recording issues, four were excluded for clearly non-cardiac chest pain, and 95 were excluded for irregular rhythm/artifacts. Among the included 795 patients, 247 (31%) met the primary outcome of 30-day MACE. Table 1 shows patient baseline characteristics. Patients with the primary outcome were older (mean age 61 years vs. 59 years, p=0.035) and had a higher proportion of males (76.1% vs. 64.6%, p=0.002). There were no statistically significant differences between MACE and non-MACE groups in terms of patient ethnicity. Factors such as history of diabetes and current smoking status were significantly more prevalent in the group with MACE. 8 Descriptive analyses of HRV and HRnV parameters are tabulated in Table 2 . In this clinical case study, was set as 3, thus HR2V, HR2V1, HR3V, HR3V1 and HR3V2 parameters were calculated. Among time domain parameters such as mean NN, SDNN and RMSSD, the HRnV and HRnVm values were generally incremental with an increase in . Notably, HR2V NN50 and HR3V NN50 were much lower than conventional HRV NN50. Moreover, NN50n and pNN50n are parameters specifically applicable to the HRnV representation. Like time domain parameters, the same trend of changes in frequency domain parameters were observed. The magnitude of increment in VLF power and LF power was larger than that of HF power with increasing . However, one exception was the normalized HF power, whose HRnV and HRnVm parameters were smaller than that of HRV. In nonlinear analysis, the differences in Poincaré SD2 values were obvious between HRV and HRnV parameters.
HR2V SampEn and HR3V SampEn were remarkably larger compared to SampEn parameters of HRV, HR2V1, HR3V1, and HR3V2, as the confidence interval of SampEn was wide when data points were less than 200 [19] , since our ECG recordings were only five to six-minute long. HR2V1, HR3V1 and HR3V2 were free from this issue as they were calculated from overlapping RRnIm sequences where more than 200 data points were available. Table 3 presents the results of univariable analyses of HRnV and HRnVm parameters. Eleven out of 21 conventional HRV parameters were statistically significant. Additionally, 13 HR2V, six HR3V, 11 HR2V1, seven HR3V1 and 11 HR3V2 parameters were also significant. Overall, additional 115 HRnV parameters were derived, among which 48 showed statistical significance between patients who had 30-day MACE and who did not. Among all HRV and HRnV parameters, mean NN, SDNN, RMSSD, NN50, pNN50, HF power, Poincaré SD1 and SD2 appeared statistically significant in at least five out of six measures (i.e., HRV, HR2V, HR2V1, HR3V, HR3V1, and HR3V2). Furthermore, skewness, LF power, SampEn, and ApEn, which did not demonstrate statistical significance in conventional HRV analysis, became statistically significant in HRnV representation. Table 4 presents the results of multivariable analyses on HRnV and HRnVm parameters by adjusting for age and sex. Compared with the results in Table 3 , several parameters became statistically insignificant, e.g. NN50 of HR3V and HR3V2, and triangular index of HRV, HR2V, and HR3V2. On the other hand, ApEn of HR2V, HR2V1, and HR3V2 became statistically significant after the adjustment. 9 Table 5 lists the 16 variables that were selected through multivariable stepwise logistic regression, among which there were one conventional HRV parameter and seven HRnV parameters. In addition to traditional predictors of adverse cardiac outcomes such as ST segment changes and troponin, HR2V ApEn (OR=0.095; 95% CI 0.014-0.628), HR2V1 ApEn (OR=19.700; 95% CI 2.942-131.900) and HR3V skewness (1.560; 95% CI 1.116-2.181) also demonstrated strong predictive power in assessing the risk of 30-day MACE. Table 6 presents the results of ROC analysis in evaluating the predictive performance by the HRnV model (based on LOOCV), HEART, TIMI, and GRACE scores. The HRnV model achieved the highest AUC value and outperformed HEART, TIMI, and GRACE scores in terms of specificity, PPV, and NPV at the optimal cut-off scores, defined as the points nearest to the upper-left corner of the ROC curves.
Discussion
HRV has been well investigated in the past decades [18, 19, 29] . While the majority of efforts in HRV research were focused on development of advanced nonlinear techniques to derive novel parameters [30, 31] , few investigated alternative approaches to analyze RRIs. Vollmer
[32] used relative RRIs to describe the relative variation of consecutive RRIs, with which HRV was analyzed. Likewise, we proposed a novel HRnV representation, providing additional HRnV parameters than conventional HRV analysis. In this paper, we introduced two measures of HRnV, namely HRnV and HRnVm. HRnV is calculated based on nonoverlapped RRnI sequences, while HRnVm is computed from overlapped RRnIm sequences.
HRnV is not developed to replace the conventional HRV; instead, this representation is a natural extension of HRV. It enables the creation of additional parameters from raw ECGs, and thus empowers the extraction of supplementary information.
In our clinical case study, we investigated the predictive value of HRnV parameters to assess the risk of 30-day MACE for chest pain patients in the ED. In addition to 21 HRV parameters, 115 HRnV parameters were derived, of which 48 were found to be statistically significant in their association with the primary outcome. Notably, even with a small (three in our study), newly generated HRnV parameters have greatly boosted the number of candidate predictors.
When longer ECG records are available, more HRnV parameters can be calculated. With HRnV parameters, HRV parameters, vital signs, and several established risk factors, we conducted multivariable logistic regression analysis and selected age, diastolic BP, pain score, ST-elevation, ST-depression, Q wave, cardiac history, troponin, HRV NN50, and seven HRnV parameters. In addition to traditional risk factors like ST segment changes, HR2V ApEn, HR2V1 ApEn, and HR3V skewness were found as strong predictors for 30-day MACE.
Comparing with the HEART, TIMI, and GRACE scores, the HRnV model achieved the highest AUC, specificity, PPV, and NPV values at the optimal cut-off points in ROC analysis.
Therefore, HRnV may be clinically useful in determining the risk of 30-day MACE for ED patients with chest pain.
Due to the wide differential diagnosis for chest pain, accurate stratification is vital, particularly for preventing low-risk patients from obtaining expensive and unnecessary medical testing and intervention [3] . The TIMI and GRACE scores have been validated for risk prediction of patients with chest pain in the ED [4, 33, 34] . However, because they were originally developed for post-acute myocardial infarction, certain criteria within the TIMI and GRACE scores may be inappropriate for the undifferentiated chest pain cohorts in the ED [1] .
In comparison, the HEART score was derived from a population of ED patients with chest pain, and has been extensively validated worldwide [10, 13, 27, 35] . It has proven its applicability in identifying both low-risk patients for possible early discharge and high-risk patients for urgent intervention. Built upon established scores, many chest pain pathways [14, [36] [37] [38] [39] reported that the HEART score achieved both sensitivity and NPV of 100% in several validation studies. Furthermore, a cost-effectiveness study conducted in Brisbane, Australia reported economic benefits by adopting an ADP in the ED, with its associated reduction in expected cost and length of stay amongst patients with chest pain [40] .
Most established clinical scores use conventional risk factors such as biomarkers, medical history, and presenting vital signs. However, patient history can sometimes be subjective and blood tests, such as troponin, take time to result. HRV, as a noninvasive measure, can be easily calculated from ECGs; it is an objective tool to assess the activities of the ANS [19] . It also has the advantage of requiring only several minutes to acquire (five to six minutes in our protocol), which is much faster than serum biomarkers. Over the past decades, HRV has been 11 widely investigated in a broad range of clinical applications, particularly in cardiovascular research. HRV was found to be closely associated with sudden cardiac death [18] . It also showed significant correlations with adverse clinical outcomes in prehospital setting [41] and with MACE outcomes in ED patients with chest pain [17] . HRV parameters have been integrated with other risk factors into machine learning algorithms to predict adverse outcomes [42, 43] . These promising results motivated the use of HRV to develop objective and computerized risk stratification tools for chest pain patients [44, 45] . In an updated review of clinical scores for chest pain, Liu et al. [5] summarized several studies which aimed to develop alternative techniques for risk stratification.
This study aimed to present the novel HRnV representation and its measures and investigate their association with clinical outcomes. Although the HRnV parameters showed promising performance in identifying high-risk chest pain patients, this study was not intended to create a ready-to-use clinical tool. Instead, we have demonstrated the feasibility of utilizing HRnV parameters to augment conventional HRV and risk factors in designing a prediction tool/score. These HRnV parameters can be readily calculated without the collection of supplementary data. In this study, with five to six-minute ECG and = 3, five-fold more HRnV parameters were calculated compared to HRV alone. When longer ECGs are available and parameter is set as a larger number, more HRnV parameters can be derived. To build a HRnV-based risk stratification tool, a systematic approach is needed to derive a point-based, consistent score to ease its clinical application and practical implementation.
As a natural extension of conventional HRV, HRnV representation creates the opportunity to generate additional parameters. This representation could also serve as a smoother for RRIs, making them less sensitive to sudden changes caused by abnormal heart beats (e.g., very short or very long RRI). However, since HRnV is a novel representation of beat-to-beat variations in ECG, many technical issues need to be addressed in future research. For instance, as shown in Table 2 , SampEn became larger when the available number of data points was less than 200 [19] , suggesting that additional research is required to investigate its applicability to short ECG records. Moreover, parameters NN50n and pNN50n are newly introduced in HRnV representation only. They characterize the number of times that the absolute difference between two successive RRnI sequences exceeds 50×n ms, by assuming that the absolute difference may be magnified when the corresponding RRnI is times longer than RRI. Thus, in-depth investigations are required in the selection of appropriate thresholds.
More importantly, physiological interpretations of the HRnV parameters and their normal values [29] need to be determined through numerous research. One example is the identification of frequency bands that correlate with certain physiological phenomenon. In the current analysis, the conventional cut-off values were adopted (i.e., ≤0.04 Hz as very low frequency range; 0.04-0.15 Hz as low frequency range; 0.15-0.4 Hz as high frequency range).
With the increase in n, frequency domain analysis may need to be changed accordingly.
Beyond its use in risk stratification of ED patients with chest pain, HRnV foresees potentials in many clinical domains where conventional HRV has been extensively investigated [46] [47] [48] [49] .
With the augmented RRnI and RRnIm sequences, HRnV could possibly capture more dynamic changes in cardiac rhythms than HRV. This capability enables the extraction of extra information from limited raw ECGs. This study utilized HRnV parameters as independent risk factors and analyzed them with traditional biostatistical methods. There are multiple ways to use HRnV parameters, e.g., each set of HRnV parameters can be analyzed individually and are subsequently combined with an ensemble learning [50] (a special type of machine learning algorithm) architecture to reach a decision. However, artificial intelligence and machine learning methods generally create black-box predictive models, making interpretation a challenge [51] .
Limitations
This study has several limitations. First, no scoring tool was developed for practical clinical use. The primary aim of this study was to demonstrate the feasibility of using HRnV parameters and common risk factors to build predictive models. Second, the HRnV model was evaluated with LOOCV strategy due to small sample size. Ideally, separate patient cohorts are needed to train and test prediction models. When a new scoring tool is developed, it is necessary to conduct external validations on cohorts with diverse patient characteristics.
Furthermore, properly designed clinical pathways are needed as well. Third, the patients included in this study were mainly from the high acuity group, resulting in a higher 30-day MACE rate (i.e., 31%) compared to other similar studies [10, 39] . As a result, the generalizability of the HRnV model developed in this study may be uncertain in other patient cohorts. Fourth, the calculated HRnV and HRV parameters depended on the choice of tools and methods for ECG signal analysis. Thus, the values of these parameters may vary across studies. Lastly, the physiology of HRnV and interpretations of its measures are mostly 13 unknown; calculation of some parameters also needs to be standardized. All these require future collaborative efforts between clinicians and scientists to address.
Conclusions
In this study, we proposed a novel HRnV representation and investigated the use of HRnV and established risk factors to develop a predictive model for risk stratification of patients with chest pain in the ED. Multiple HRnV parameters were found as statistically significant predictors, which effectively augmented conventional HRV, vital signs, troponin, and cardiac risk factors in building an effective model with good discrimination performance. The HRnV model outperformed the HEART, TIMI, and GRACE scores in the ROC analysis. It also demonstrated its capability in identifying low-risk patients, which may enable its use in building a new clinical pathway. Moving forward, we suggest further development of a pointbased, ready-to-use HRnV risk stratification tool. Although some issues remain to be addressed, we hope to stimulate a new stream of research on HRnV. We believe that future endeavors in this field will lead to the possibility of in-depth evaluation of the associations between HRnV measures and various human diseases. 
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